contact[at]op2lysis.com

pilelabs
  • The company
  • The Technology
  • Products
  • Indications
  • News
  • Contact
  • Français

Monthly Archives: July 2023

  1. Home
  2. 2023
  3. July
  • Jérôme Parcq
  • July 2023
  • Press Release
New support from Bpifrance for €1.5M, covering the GMP production of the Drug Substance OptPA, has been obtained

Op2Lysis was awarded a Deeptech Development Grant (ADD) to manufacture the clinical batch of OptPA, the active substance in O2L-001, for phase 1/2 in patients suffering from cerebral haemorrhage. The press release:

Read More

Articles récents

  • Retrospective – 2024 in a nutshell
  • Funding for the ThromboSTROKE collaborative research project
  • Sucessful DRF toxicology Study
  • Retrospective – 2023 in a nutshell
  • Nominated for the GALIEN USA 2023 award “Best Startup”

Archives

  • February 2025
  • October 2024
  • September 2024
  • January 2024
  • October 2023
  • September 2023
  • July 2023
  • January 2023
  • December 2022
  • September 2022
  • April 2022
  • January 2022

Catégories

  • Corporate
  • Event
  • Press Release
  • Technology
gym-footer-logo

Biotechnology company that researches and develops innovative medicines

Supported by
europe
bpi
wallonie

SItemap

  • Contact
  • home
  • Indications
  • Legal Notice
  • News
  • Products
  • The company
  • The Technology

Recent Posts

Nominated for the GALIEN USA 2023 award “Best Startup”
October 12, 2023
Retrospective – 2024 in a nutshell
February 01, 2025
Funding for the ThromboSTROKE collaborative research project
October 15, 2024

Contact

  • FRANCE: 117 avenue Victor Hugo, 92100 Boulogne-Billancourt, France BELGIUM: Légia Park, Boulevard Patience et Beaujonc, 3, 4000 Liège, Belgium

Op2Lysis © 2022 All Rights Reserved – Legal notice – web agency : Bridge Communication